Patent: 8,557,831
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 8,557,831
Title: | Compositions and methods for treatment and prevention of insulin resistance |
Abstract: | Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.2 to 5.5 mg/dl. |
Inventor(s): | Johnson; Richard J. (Gainesville, FL), Nakagawa; Takahiko (Gainesville, FL) |
Assignee: | University of Florida Research Foundation, Inc. (Gainesville, FL) |
Application Number: | 11/572,270 |
Patent Claims: | see list of patent claims |
Details for Patent 8,557,831
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Sanofi-aventis U.s. Llc | ELITEK | rasburicase | For Injection | 103946 | 07/12/2002 | ⤷ Try a Trial | 2024-07-21 |
Sanofi-aventis U.s. Llc | ELITEK | rasburicase | For Injection | 103946 | 01/06/2006 | ⤷ Try a Trial | 2024-07-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |